ANGO Quote, Financials, Valuation and Earnings

Accuray has a net margin of -6.12% compared to AngioDynamics's net margin of -1.15%. AngioDynamics's return on equity of -20.83% beat Accuray's return on equity of 1.47%.

AngioDynamics has a consensus price target of $15.67, signalling upside risk potential of 53.44%. On the other hand Accuray has an analysts' consensus of $5.17 which suggests that it could grow by 285.57%. Given that Accuray has higher upside potential than AngioDynamics, analysts believe Accuray is more attractive than AngioDynamics.

AngioDynamics has a beta of 0.619, which suggesting that the stock is 38.149% less volatile than S&P 500. In comparison Accuray has a beta of 1.302, suggesting its more volatile than the S&P 500 by 30.211%.

AngioDynamics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics pays -- of its earnings as a dividend. Accuray pays out -- of its earnings as a dividend.

AngioDynamics quarterly revenues are $72M, which are smaller than Accuray quarterly revenues of $113.2M. AngioDynamics's net income of -$4.4M is lower than Accuray's net income of -$1.3M. Notably, AngioDynamics's price-to-earnings ratio is -- while Accuray's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics is 1.47x versus 0.29x for Accuray. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of -6.12% compared to AngioDynamics's net margin of -5.14%. AngioDynamics's return on equity of -20.83% beat Integer Holdings's return on equity of 4.85%.

AngioDynamics has a consensus price target of $15.67, signalling upside risk potential of 53.44%. On the other hand Integer Holdings has an analysts' consensus of $148.75 which suggests that it could grow by 23.14%. Given that AngioDynamics has higher upside potential than Integer Holdings, analysts believe AngioDynamics is more attractive than Integer Holdings.

AngioDynamics has a beta of 0.619, which suggesting that the stock is 38.149% less volatile than S&P 500. In comparison Integer Holdings has a beta of 0.979, suggesting its less volatile than the S&P 500 by 2.088%.

AngioDynamics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

AngioDynamics quarterly revenues are $72M, which are smaller than Integer Holdings quarterly revenues of $437.4M. AngioDynamics's net income of -$4.4M is higher than Integer Holdings's net income of -$22.5M. Notably, AngioDynamics's price-to-earnings ratio is -- while Integer Holdings's PE ratio is 57.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics is 1.47x versus 2.44x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of -6.12% compared to AngioDynamics's net margin of -45.89%. AngioDynamics's return on equity of -20.83% beat Masimo's return on equity of -39.91%.

AngioDynamics has a consensus price target of $15.67, signalling upside risk potential of 53.44%. On the other hand Masimo has an analysts' consensus of $183.74 which suggests that it could grow by 8.53%. Given that AngioDynamics has higher upside potential than Masimo, analysts believe AngioDynamics is more attractive than Masimo.

AngioDynamics has a beta of 0.619, which suggesting that the stock is 38.149% less volatile than S&P 500. In comparison Masimo has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.725%.

AngioDynamics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

AngioDynamics quarterly revenues are $72M, which are smaller than Masimo quarterly revenues of $372M. AngioDynamics's net income of -$4.4M is higher than Masimo's net income of -$170.7M. Notably, AngioDynamics's price-to-earnings ratio is -- while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics is 1.47x versus 4.65x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

ZimVie has a net margin of -6.12% compared to AngioDynamics's net margin of -1.31%. AngioDynamics's return on equity of -20.83% beat ZimVie's return on equity of -4.97%.

AngioDynamics has a consensus price target of $15.67, signalling upside risk potential of 53.44%. On the other hand ZimVie has an analysts' consensus of $11.67 which suggests that it could grow by 30.21%. Given that AngioDynamics has higher upside potential than ZimVie, analysts believe AngioDynamics is more attractive than ZimVie.

AngioDynamics has a beta of 0.619, which suggesting that the stock is 38.149% less volatile than S&P 500. In comparison ZimVie has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

AngioDynamics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ZimVie offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics pays -- of its earnings as a dividend. ZimVie pays out -- of its earnings as a dividend.

AngioDynamics quarterly revenues are $72M, which are smaller than ZimVie quarterly revenues of $112M. AngioDynamics's net income of -$4.4M is lower than ZimVie's net income of -$1.5M. Notably, AngioDynamics's price-to-earnings ratio is -- while ZimVie's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics is 1.47x versus 0.56x for ZimVie. Usually stocks with elevated PS ratios are considered overvalued.